Recent developments regarding voltage-gated sodium channel blockers for the treatment of inherited and acquired neuropathic pain syndromes

Frontiers in Pharmacology

Volumn OCT, Issue , 2011, Pages

  Theile, Jonathan W ^a   Cummins, Theodore R ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Nav1.7; Nav1.8; Neuropathic pain; Resurgent currents; TRPV1; Voltage gated sodium channel

Indexed keywords

227 C 89; A 803476; A 887826; AMBROXOL; AMITRIPTYLINE; BENZAZEPINONE DERIVATIVE; BIPHENYLPYRAZOLE DERIVATIVE; BIPHENYLTHIAZOLE CARBOXAMIDE DERIVATIVE; BUPIVACAINE; CAPSAICIN; CARBAMAZEPINE; EUGENOL; HARKOSERIDE; IMIDAZOPYRIDINE DERIVATIVE; LIDOCAINE; LIDOCAINE ETHOBROMIDE; LOCAL ANESTHETIC AGENT; MEXILETINE; MU O CONOTOXIN MRVIB; N [1 (7 CHLORO 1 ISOPROPYL 2 OXO 2,3,4,5 TETRAHYDRO 1H BENZO[B]AZEPIN 3 YLCARBAMOYL) 2 (2 FLUOROPHENYL)ETHYL] 4 FLUORO 2 TRIFLUOROMETHYLBENZAMIDE; N METHYLAMITRIPTYLINE; PROTX 2; RALFINAMIDE; TETRACAINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; V 102862; VANILLOID RECEPTOR AGONIST; VOLTAGE GATED SODIUM CHANNEL; VOLTAGE GATED SODIUM CHANNEL BLOCKING AGENT; XEN 402; Z 123212;

ACTION POTENTIAL; ALLODYNIA; ARTICLE; AXONAL INJURY; BINDING AFFINITY; BLOOD BRAIN BARRIER; CLINICAL FEATURE; CONGENITAL ANALGESIA; DISEASE ACTIVITY; DRUG BINDING; DRUG BINDING SITE; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG SELECTIVITY; DRUG SENSITIVITY; DRUG TARGETING; DRUG TRANSPORT; ENZYME INACTIVATION; ERYTHROMELALGIA; EVOKED RESPONSE; GAIN OF FUNCTION MUTATION; GENE; GENE MUTATION; GENETIC ASSOCIATION; GENETIC DISORDER; GENETIC POLYMORPHISM; HUMAN; HYPERALGESIA; HYPOALGESIA; IC 50; IN VIVO STUDY; INFLAMMATORY PAIN; MONOTHERAPY; NERVE BLOCK; NERVE CELL EXCITABILITY; NERVE CELL MEMBRANE STEADY POTENTIAL; NERVE COMPRESSION; NEUROPATHIC PAIN; NEUROTRANSMISSION; NOCICEPTION; NONHUMAN; PAIN; PAIN THRESHOLD; PAROXYSMAL EXTREME PAIN DISORDER; POSTHERPETIC NEURALGIA; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; PROTEIN LOCALIZATION; PROTEIN TARGETING; SCIATIC NERVE; SCN10A GENE; SCN9A GENE; SENSORY NERVE CELL; SYMPATHETIC NERVE CELL; VISCERAL PAIN;

EID: 84865619737     PISSN: None     EISSN: 16639812     Source Type: Journal    
DOI: 10.3389/fphar.2011.00054     Document Type: Article

References (137)

1. Akopian,A. N., Sivilotti, L., and Wood, J. N. (1996). A tetrodotoxin-resistant voltage-gated sodium channel expressed by sensory neurons. Nature 379, 257-262.
2. Akopian,A. N., Souslova,V., England, S., Okuse, K., Ogata, N., Ure, J., Smith, A., Kerr, B. J., Mcmahon, S. B., Boyce, S., Hill, R., Stanfa, L. C., Dickenson, A. H., and Wood, J. N. (1999). The tetrodotoxin-resistant sodium channel SNS has a specialized function in pain pathways. Nat. Neurosci. 2, 541-548.
3. Amaya, F., Wang, H., Costigan, M., Llchorne, A. J., Hatcher, J. P., Egerton, J., Stean, T., Morisset, V., Grose, D., Gunthorpe, M. J., Chessell, I. P., Tate, S., Green, P. J., and Woolf, C. J. (2006). The voltage-gated sodium channel Na(v)1.9 is an effector of peripheral inflammatory pain hypersensitivity. J. Neurosci. 26, 12852-12860.
4. Baker, M. D., Chandra, S. Y., Ding, Y., Waxman, S. G., and Wood, J. N. (2003). GTP-induced tetrodotoxin-resistant Na+ current regulates excitability in mouse and rat small diameter sensory neurones. J. Phys-iol. (Lond.) 548, 373-382.
5. Bant, J. S., and Raman, I. M. (2010). Control of transient, resurgent, and persistent current by open-channel block by Na channel β4 in cultured cerebellar granule neurons. Proc. Natl. Acad. Sci. U.S.A. 107, 12357-12362.
6. Bee, L. A., and Dickenson, A. H. (2009). Effects of lacosamide, a novel sodium channel modulator, on dorsal horn neuronal responses in a rat model of neuropathy. Neuropharmacology 57, 472-479.
7. Beggs, S., Liu, X. J., Kwan, C., and Salter, M. W. (2010). Peripheral nerve injury and TRPV1-expressing primary afferent C-fibers cause opening of the blood-brain barrier. Mol. Pain 6, 74.
8. Bensimon, G., Lacomblez, L., and Meininger, V. (1994). A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. N. Engl. J. Med. 330, 585-591.
9. Beyreuther, B., Callizot, N., and Stohr, T. (2006). Antinociceptive efficacy of lacosamide in a rat model for painful diabetic neuropathy. Eur. J. Pharmacol. 539, 64-70.
10. Binshtok, A. M., Bean, B. P., and Woolf, C. J. (2007). Inhibition of nocicep-tors by TRPV1-mediated entry of impermeant sodium channel block-ers. Nature 449, 607-610.
11. Binshtok, A. M., Gerner, P., Oh, S. B., Puopolo, M., Suzuki, S., Rober-son, D. P., Herbert, T., Wang, C. F., Kim, D., Chung, G., Mitani, A. A., Wang, G. K., Bean, B. P., and Woolf, C. J. (2009). Coapplication of lido-caine and the permanently charged sodium channel blocker QX-314 produces a long-lasting nociceptive blockade in rodents. Anesthesiology 111, 127-137.
12. Black, J. A., Liu, S., Tanaka, M., Cummins, T. R., and Waxman, S. G. (2004). Changes in the expression of tetrodotoxin-sensitive sodium channels within dorsal root ganglia neurons in inflammatory pain. Pain 108, 237-247.
13. Bosmans, F., Puopolo, M., Martin-Eauclaire, M. F., Bean, B. P., and Swartz, K. J. (2011). Functional properties and toxin pharmacology of a dorsal root ganglion sodium channel viewed through its voltage sensors. J. Gen. Physiol. 138, 59-72.
14. Bregman, H., Berry, L., Buchanan, J. L., Chen, A., Du, B., Feric, E., Hierl, M., Huang, L., Immke, D., Janosky, B., Johnson, D., Li, X., Ligutti, J., Liu, D., Malmberg, A., Matson, D., Mcder-mott, J., Miu, P., Nguyen, H. N., Patel, V. F., Waldon, D., Wilenkin, B., Zheng, X. M., Zou, A., Mcdonough, S. I., and Dimauro, E. F. (2011). Identification of a potent, state-dependent inhibitor of Nav1.7 with oral efficacy in the formalin model of persistent pain. J. Med. Chem. 54, 4427-4445.
15. Browne, L. E., Clare, J. J., and Wray, D. (2009). Functional and pharmacological properties of human and rat NaV1.8 channels. Neuropharmacol-ogy 56, 905-914.
16. Casey, G. P., Roberts, J. S., Paul, D., Diamond, I., and Gould, H. J. III. (2010). Ranolazine attenuation of CFA-induced mechanical hyperalge-sia. Pain Med. 11, 119-126.
17. Castelli, L., Biella, G., Toselli, M., and Magistretti, J. (2007). Resurgent Na+ current in pyramidal neurones of rat perirhinal cortex: axonal location of channels and contribution to depolarizing drive during repetitive firing. J. Physiol. (Lond.) 582, 1179-1193.
18. Caterina, M. J., Schumacher, M. A., Tominaga, M., Rosen, T. A., Levine, J. D., and Julius, D. (1997). The cap-saicin receptor: a heat-activated ion channel in the pain pathway. Nature 389, 816-824.
19. Catterall, W. A. (2000). From ionic currents to molecular mechanisms: the structure and function of voltage-gated sodium channels. Neuron 26, 13-25.
20. Catterall, W. A., Goldin, A. L., and Waxman, S. G. (2005). International Union of Pharmacology. XLVII. Nomenclature and structure-function relationships of voltage-gated sodium channels. Pharmacol. Rev. 57, 397-409.
21. Chen, X., Pang, R. P., Shen, K. F., Zim-mermann, M., Xin, W. J., Li, Y. Y., and Liu, X. G. (2011). TNF-alpha enhances the currents of voltage gated sodium channels in uninjured dorsal root ganglion neurons following motor nerve injury. Exp. Neurol. 227, 279-286.
22. Cheramy, A., Barbeito, L., Godeheu, G., and Glowinski, J. (1992). Riluzole inhibits the release of glutamate in the caudate nucleus of the cat in vivo. Neurosci. Lett. 147, 209-212.
23. Choi, J. S., Dib-Hajj, S. D., and Waxman, S. G. (2006). Inherited erythermal-gia: limb pain from an S4 charge-neutral Na channelopathy. Neurology 67, 1563-1567.
24. Cox, J. J., Reimann, F., Nicholas, A. K., Thornton, G., Roberts, E., Springell, K., Karbani, G., Jafri, H., Mannan, J., Raashid, Y., Al-Gazali, L., Hamamy, H., Valente, E. M., Gorman, S., Williams, R., Mchale, D. P., Wood, J. N., Gribble, F. M., and Woods, C. G. (2006). An SCN9A chan-nelopathy causes congenital inability to experience pain. Nature 444, 894-898.
25. Cummins, T. R., Dib-Hajj, S. D., Black, J. A., Akopian, A. N., Wood, J. N., and Waxman, S. G. (1999). A novel persistent tetrodotoxin-resistant sodium current in SNS-null and wild-type small primary sensory neurons. J. Neurosci. 19, RC43.
26. Cummins, T. R., Dib-Hajj, S. D., Her-zog, R. I., and Waxman, S. G. (2005). Nav1.6 channels generate resurgent sodium currents in spinal sensory neurons. FEBS Lett. 579, 2166-2170.
27. Cummins, T. R., Dib-Hajj, S. D., and Waxman, S. G. (2004). Electrophysi-ological properties of mutant Nav1.7 sodium channels in a painful inherited neuropathy. J. Neurosci. 24, 8232-8236.
28. Cummins, T. R., Howe, J. R., and Wax-man, S. G. (1998). Slow closed-state inactivation: a novel mechanism underlying ramp currents in cells expressing the hNE/PN1 sodium channel. J. Neurosci. 18, 9607-9619.
29. Cummins, T. R., and Waxman, S. G. (1997). Downregulation of tetrodotoxin-resistant sodium currents and upregulation of a rapidly repriming tetrodotoxin-sensitive sodium current in small spinal sensory neurons after nerve injury. J. Neurosci. 17, 3503-3514.
30. Debono, M. W., Le Guern, J., Canton, T., Doble, A., and Pradier, L. (1993). Inhibition by riluzole of elec-trophysiological responses mediated by rat kainate and NMDA receptors expressed in Xenopus oocytes. Eur. J. Pharmacol. 235, 283-289.
31. Decosterd, I., Ji, R. R., Abdi, S., Tate, S., and Woolf, C. J. (2002). The pattern of expression of the voltage-gated sodium channels Na(v)1.8 and Na(v)1.9 does not change in uninjured primary sensory neurons in experimental neuropathic pain models. Pain 96, 269-277.
32. Devor, M. (2006). Sodium channels and mechanisms of neuropathic pain. J. Pain 7, S3-S12.
33. Dib-Hajj, S. D., Estacion, M., Jarecki, B. W., Tyrrell, L., Fischer, T. Z., Lawden, M., Cummins, T. R., and Waxman, S. G. (2008). Paroxysmal extreme pain disorder M1627K mutation in human Nav1.7 renders DRG neurons hyperexcitable. Mol. Pain 4, 37.
34. Dib-Hajj, S. D., Rush, A. M., Cummins, T. R., Hisama, F. M., Novella, S., Tyrrell, L., Marshall, L., and Wax-man, S. G. (2005). Gain-of-function mutation in Nav1.7 in familial erythromelalgia induces bursting of sensory neurons. Brain 128, 1847-1854.
35. Dib-Hajj, S. D., Tyrrell, L., Cummins, T. R., Black, J. A., Wood, P. M., and Waxman, S. G. (1999). Two tetrodotoxin-resistant sodium channels in human dorsal root ganglion neurons. FEBS Lett. 462, 117-120.
36. Djouhri, L., Fang, X., Okuse, K., Wood, J. N., Berry, C. M., and Lawson, S. N. (2003). The TTX-resistant sodium channel Nav1.8 (SNS/PN3): expression and correlation with membrane properties in rat nociceptive primary afferent neurons. J. Physiol. 550, 739-752.
37. Ekberg, J., Jayamanne, A., Vaughan, C. W., Aslan, S., Thomas, L., Mould, J., Drinkwater, R., Baker, M. D., Abra-hamsen, B., Wood, J. N., Adams, D. J., Christie, M. J., and Lewis, R. J. (2006). muO-conotoxin MrVIB selectively blocks Nav1.8 sensory neuron specific sodium channels and chronic pain behavior without motor deficits. Proc. Natl. Acad. Sci. U.S.A. 103, 17030-17035.
38. England, S., and De Groot, M. J. (2009). Subtype-selective targeting of voltage-gated sodium channels. Br. J. Pharmacol. 158, 1413-1425.
39. Errington, A. C., Stohr, T., Heers, C., and Lees, G. (2008). The investiga-tional anticonvulsant lacosamide selectively enhances slow inacti-vation of voltage-gated sodium channels. Mol. Pharmacol. 73, 157-169.
40. Estacion, M., Dib-Hajj, S. D., Benke, P. J., Te Morsche, R. H., Eastman, E. M., Macala, L. J., Drenth, J. P., and Waxman, S. G. (2008). NaV1.7 gain-of-function mutations as a continuum: A1632E displays physiological changes associated with erythromelalgia and paroxysmal extreme pain disorder mutations and produces symptoms of both disorders. J. Neurosci. 28, 11079-11088.
41. Estacion, M., Waxman, S. G., and Dib-Hajj, S. D. (2010). Effects of ranolazine on wild-type and mutant hNav1.7 channels and on DRG neuron excitability. Mol. Pain 6, 35.
42. Felts, P. A., Yokoyama, S., Dib-Hajj, S., Black, J. A., and Waxman, S. G. (1997). Sodium channel alpha-subunit mRNAs I, II, III, NaG, Na6 and hNE (PN1): different expression patterns in developing rat nervous system. Brain Res. Mol. Brain Res. 45, 71-82.
43. Fertleman, C. R., Baker, M. D., Parker, K. A., Moffatt, S., Elmslie, F. V., Abrahamsen, B., Ostman, J., Klug-bauer, N., Wood, J. N., Gardiner, R. M., and Rees, M. (2006). SCN9A mutations in paroxysmal extreme pain disorder: allelic variants underlie distinct channel defects and phe-notypes. Neuron 52, 767-774.
44. Fertleman, C. R., Ferrie, C. D., Aicardi, J., Bednarek, N. A., Eeg-Olofsson, O., Elmslie, F. V., Griese-mer, D. A., Goutieres, F., Kirkpatrick, M., Malmros, I. N., Pollitzer, M., Rossiter, M., Roulet-Perez, E., Schubert, R., Smith, V. V., Testard, H., Wong, V., and Stephenson, J. B. (2007). Paroxysmal extreme pain disorder (previously familial rectal pain syndrome). Neurology 69, 586-595.
45. Gaida, W., Klinder, K., Arndt, K., and Weiser, T. (2005). Ambroxol, a Nav1.8-preferring Na(+) channel blocker, effectively suppresses pain symptoms in animal models of chronic, neuropathic and inflammatory pain. Neuropharmacology 49, 1220-1227.
46. Gerner, P., Binshtok, A. M., Wang, C. F., Hevelone, N. D., Bean, B. P., Woolf, C. J., and Wang, G. K. (2008). Cap-saicin combined with local anesthetics preferentially prolongs sen-sory/nociceptive block in rat sciatic nerve. Anesthesiology 109, 872-878.
47. Goldin, A. L. (2003). Mechanisms of sodium channel inactiva-tion. Curr. Opin. Neurobiol. 13, 284-290.
48. Goldin, A. L., Barchi, R. L., Caldwell, J. H., Hofmann, F., Howe, J. R., Hunter, J. C., Kallen, R. G., Man-del, G., Meisler, M. H., Netter, Y. B., Noda, M.,Tamkun,M. M.,Waxman, S. G., Wood, J. N., and Catterall, W. A. (2000). Nomenclature of voltage-gated sodium channels. Neuron 28, 365-368.
49. Gould, H. J. III, Garrett, C., Donahue, R. R., Paul, D., Diamond, I., and Taylor, B. K. (2009). Ranolazine attenuates behavioral signs of neuropathic pain. Behav. Pharmacol. 20, 755-758.
50. Grieco, T. M., Malhotra, J. D., Chen, C., Isom, L. L., and Raman, I. M. (2005). Open-channel blockbythecytoplas-mic tail of sodium channel beta4 as a mechanism for resurgent sodium current. Neuron 45, 233-244.
51. Grieco, T. M., and Raman, I. M. (2004). Production of resurgent current in NaV1.6-null Purkinje neurons by slowing sodium channel inactiva-tion with beta-pompilidotoxin. J. Neurosci. 24, 35-42.
52. Hains, B. C., Klein, J. P., Saab, C. Y., Craner, M. J., Black, J. A., and Waxman, S. G. (2003). Upregu-lation of sodium channel Nav1.3 and functional involvement in neu-ronal hyperexcitability associated with central neuropathic pain after spinal cord injury. J. Neurosci. 23, 8881-8892.
53. Hama, A., and Sagen, J. (2011). Antinociceptive effect of riluzole in rats with neuropathic spinal cord injury pain. J. Neurotrauma 28, 127-134.
54. Hama, A. T., Plum, A. W., and Sagen, J. (2010). Antinociceptive effect of ambroxol in rats with neuropathic spinal cord injury pain. Pharmacol. Biochem. Behav. 97, 249-255.
55. Hao, J. X., Stohr, T., Selve, N., Wiesenfeld-Hallin, Z., and Xu, X. J. (2006). Lacosamide, a new anti-epileptic, alleviates neuropathic pain-like behaviors in rat models of spinal cord or trigeminal nerve injury. Eur. J. Pharmacol. 553, 135-140.
56. He, X. H., Zang, Y., Chen, X., Pang, R. P., Xu, J. T., Zhou, X., Wei, X. H., Li, Y. Y., Xin, W. J., Qin, Z. H., and Liu, X. G. (2010). TNF-alpha contributes to up-regulation of Nav1.3 and Nav1.8 in DRG neurons following motor fiber injury. Pain 151, 266-279.
57. Herzog, R. I., Cummins, T. R., Ghas-semi, F., Dib-Hajj, S. D., and Wax-man, S. G. (2003). Distinct reprim-ing and closed-state inactivation kinetics of Nav1.6 and Nav1.7 sodium channels in mouse spinal sensory neurons. J. Physiol. 551, 741-750.
58. Herzog, R. I., Cummins, T. R., and Wax-man, S. G. (2001). Persistent TTX-resistant Na+ current affects resting potential and response to depolarization in simulated spinal sensory neurons. J. Neurophysiol. 86, 1351-1364.
59. Hildebrand, M. E., Smith, P. L., Bladen, C., Eduljee, C., Xie, J. Y., Chen, L., Fee-Maki, M., Doering, C. J., Mezeyova, J., Zhu, Y., Belardetti, F., Pajouhesh, H., Parker, D., Arneric, S. P., Parmar, M., Porreca, F.,Tringham, E., Zamponi, G. W., and Snutch, T. P. (2011). A novel slow-inactivation-specific ion channel modulator attenuates neuropathic pain. Pain 152, 833-843.
60. Ho, C., and O'leary, M. E. (2011). Single-cell analysis of sodium channel expression in dorsal root ganglion neurons. Mol. Cell. Neurosci. 46, 159-166.
61. Hodgkin,A.L.,and Huxley,A.F. (1952). A quantitative description of membrane current and its application to conduction and excitation in nerve. J. Physiol. (Lond.) 117, 500-544.
62. Hoyt, S. B., London, C., Gorin, D., Wyvratt, M. J., Fisher, M. H., Abbadie, C., Felix, J. P., Garcia, M. L., Li, X., Lyons, K. A., Mcgowan, E., Macintyre, D. E., Martin, W. J., Priest, B. T., Ritter, A., Smith, M. M., Warren, V. A., Williams, B. S., Kac-zorowski, G. J., and Parsons, W. H. (2007a). Discovery of a novel class of benzazepinone Na(v)1.7 blockers: potential treatments for neuropathic pain. Bioorg. Med. Chem. Lett. 17, 4630-4634.
63. Hoyt, S. B., London, C., Ok, H., Gonzalez, E., Duffy, J. L., Abbadie, C., Dean, B., Felix, J. P., Garcia, M. L., Jochnowitz, N., Karanam, B. V., Li, X., Lyons, K. A., Mcgowan, E., Macintyre, D. E., Martin, W. J., Priest, B. T., Smith, M. M., Tschirret-Guth, R., Warren, V. A., Williams, B. S., Kaczorowski, G. J., and Parsons, W. H. (2007b). Benzazepinone Nav1.7 blockers: potential treatments for neuropathic pain. Bioorg. Med. Chem. Lett. 17, 6172-6177.
64. Jarecki, B. W., Piekarz, A. D., Jackson, J. O. II, and Cummins, T. R. (2010). Human voltage-gated sodium channel mutations that cause inherited neuronal and muscle channelopathies increase resurgent sodium currents. J. Clin. Invest. 120, 369-378
65. Jarecki, B. W., Sheets, P. L., Jackson, J. O. II, and Cummins, T. R. (2008). Paroxysmal extreme pain disorder mutations within the D3/S4-S5 linker of Nav1.7 cause moderate destabilization of fast inactivation. J. Physiol. 586, 4137-4153.
66. Jarvis, M. F., Honore, P., Shieh, C. C., Chapman, M., Joshi, S., Zhang, X. F., Kort, M., Carroll, W., Marron, B., Atkinson, R., Thomas, J., Liu, D., Krambis, M., Liu, Y., Mcgaraughty, S., Chu, K., Roeloffs, R., Zhong, C., Mikusa, J. P., Hernandez, G., Gauvin, D.,Wade, C., Zhu, C., Pai, M., Scanio, M., Shi, L., Drizin, I., Gregg, R., Mat-ulenko, M., Hakeem, A., Gross, M., Johnson, M., Marsh, K., Wagoner, P. K., Sullivan, J. P., Faltynek, C. R., and Krafte, D. S. (2007). A-803467, a potent and selective Nav1.8 sodium channel blocker, attenuates neuropathic and inflammatory pain in the rat. Proc. Natl. Acad. Sci. U.S.A. 104, 8520-8525.
67. Jo, S., and Bean, B. P. (2011). Inhibition of neuronal voltage-gated sodium channels by brilliant blue G. Mol. Pharmacol. 80, 247-257.
68. John, V. H., Main, M. J., Powell, A. J., Gladwell, Z. M., Hick, C., Sidhu, H. S., Clare, J. J., Tate, S., and Trezise, D. J. (2004). Heterologous expression and functional analysis of rat Nav1.8 (SNS) voltage-gated sodium channels in the dorsal root ganglion neu-roblastoma cell line ND7-23. Neu-ropharmacology 46, 425-438.
69. Joshi, S. K., Mikusa, J. P., Hernandez, G., Baker, S., Shieh, C. C., Neelands, T., Zhang, X. F., Niforatos, W., Kage, K., Han, P., Krafte, D., Faltynek, C., Sullivan, J. P., Jarvis, M. F., and Honore, P. (2006). Involvement of the TTX-resistant sodium channel Nav 1.8 in inflammatory and neuropathic, but not post-operative, pain states. Pain 123, 75-82.
70. Kerr, B. J., Souslova, V., Mcmahon, S. B., and Wood, J. N. (2001). A role for the TTX-resistant sodium channel Nav 1.8 in NGF-induced hyper-algesia, but not neuropathic pain. Neuroreport 12, 3077-3080.
71. Kerr, N. C., Holmes, F. E., and Wyn-ick, D. (2004). Novel isoforms of the sodium channels Nav1.8 and Nav1.5 are produced by a conserved mechanism in mouse and rat. J. Biol. Chem. 279, 24826-24833.
72. Khaliq, Z. M., Gouwens, N. W., and Raman, I. M. (2003). The contribution of resurgent sodium current to high-frequency firing in Purkinje neurons: an experimental and modeling study. J. Neurosci. 23, 4899-4912.
73. Klugbauer, N., Lacinova, L., Flockerzi, V., and Hofmann, F. (1995). Structure and functional expression of a new member of the tetrodotoxin-sensitive voltage-activated sodium channel family from human neu-roendocrine cells. EMBO J. 14, 1084-1090.
74. Kort, M. E., Atkinson, R. N., Thomas, J. B., Drizin, I., Johnson, M. S., Secrest, M. A., Gregg, R. J., Scanio, M. J., Shi, L., Hakeem, A. H., Matulenko, M. A., Chapman, M. L., Krambis, M. J., Liu, D., Shieh, C. C., Zhang, X., Simler, G., Mikusa, J. P., Zhong, C., Joshi, S., Honore, P., Roeloffs, R., Werness, S., Antonio, B., Marsh, K. C., Fal-tynek, C. R., Krafte, D. S., Jarvis, M. F., and Marron, B. E. (2010). Subtype-selective Na(v)1.8 sodium channel blockers: identification of potent, orally active nicotinamide derivatives. Bioorg. Med. Chem. Lett. 20, 6812-6815.
75. Kort, M. E., Drizin, I., Gregg, R. J., Scanio, M. J., Shi, L., Gross, M. F., Atkinson, R. N., Johnson, M. S., Pacofsky, G. J., Thomas, J. B., Carroll, W. A., Krambis, M. J., Liu, D., Shieh, C. C., Zhang, X., Hernandez, G., Mikusa, J. P., Zhong, C., Joshi, S., Honore, P., Roeloffs,R.,Marsh,K. C., Murray, B. P., Liu, J., Werness, S., Fal-tynek, C. R., Krafte, D. S., Jarvis, M. F., Chapman, M. L., and Marron, B. E. (2008). Discovery and biological evaluation of 5-aryl-2-furfuramides, potent and selective blockers of the Nav1.8 sodium channel with efficacy in models of neuropathic and inflammatory pain. J. Med. Chem. 51, 407-416.
76. Lampert, A., Hains, B. C., and Wax-man, S. G. (2006). Upregulation of persistent and ramp sodium current in dorsal horn neurons after spinal cord injury. Exp. Brain Res. 174, 660-666.
77. Leffler, A., Fischer, M. J., Rehner, D., Kienel, S., Kistner, K., Sauer, S. K., Gavva, N. R., Reeh, P. W., and Nau, C. (2008). The vanilloid receptor TRPV1 is activated and sensitized by local anesthetics in rodent sensory neurons. J. Clin. Invest. 118, 763-776.
78. Leffler, A., Herzog, R. I., Dib-Hajj, S. D., Waxman, S. G., and Cummins, T. R. (2005). Pharmacological properties of neuronal TTX-resistant sodium channels and the role of a critical ser-ine pore residue. Pflugers Arch. 451, 454-463.
79. Leffler, A., Reckzeh, J., and Nau, C. (2010). Block of sensory neuronal Na+ channels by the secreolytic ambroxol is associated with an interaction with local anesthetic binding sites. Eur. J. Pharmacol. 630, 19-28.
80. Leo, S., D'hooge, R., and Meert, T. (2010). Exploring the role of nociceptor-specific sodium channels in pain transmission using Nav1.8 and Nav1.9 knockout mice. Behav. Brain Res. 208, 149-157.
81. London, C., Hoyt, S. B., Parsons, W. H., Williams, B. S., Warren, V. A., Tschirret-Guth, R., Smith, M. M., Priest, B. T., Mcgowan, E., Martin, W. J., Lyons, K. A., Li, X., Karanam, B. V., Jochnowitz, N., Garcia, M. L., Felix, J. P., Dean, B., Abbadie, C., Kaczorowski, G. J., and Duffy, J. L. (2008). Imidazopyridines: a novel class of hNav1.7 channel block-ers. Bioorg. Med. Chem. Lett. 18, 1696-1701.
82. Mcgaraughty, S., Chu, K. L., Scanio, M. J., Kort, M. E., Faltynek, C. R., and Jarvis, M. F. (2008). A selective Nav1.8 sodium channel blocker, A-803467 [5-(4-chlorophenyl-N-(3,5-dimethoxyphenyl)furan-2-carboxamide], attenuates spinal neuronal activity in neuropathic rats. J. Pharmacol. Exp. Ther. 324, 1204-1211.
83. Mcgowan, E., Hoyt, S. B., Li, X., Lyons, K. A., and Abbadie, C. (2009). A peripherally acting Na(v)1.7 sodium channel blocker reverses hyperal-gesia and allodynia on rat models of inflammatory and neuropathic pain. Anesth. Analg. 109, 951-958.
84. Mulroy, M. F. (2002). Systemic toxi-city and cardiotoxicity from local anesthetics: incidence and preventive measures. Reg. Anesth. Pain Med. 27, 556-561.
85. Nassar, M. A., Baker, M. D., Levato, A., Ingram, R., Mallucci, G., Mcma-hon, S. B., and Wood, J. N. (2006). Nerve injury induces robust allody-nia and ectopic discharges in Nav1.3 null mutant mice. Mol. Pain 2, 33.
86. Nassar, M. A., Levato, A., Stirling, L. C., andWood,J.N. (2005). Neuropathic pain develops normally in mice lacking both Na(v)1.7 and Na(v)1.8. Mol. Pain 1, 24.
87. Novakovic, S. D., Tzoumaka, E., Mcgivern, J. G., Haraguchi, M., Sangameswaran, L., Gogas, K. R., Eglen, R. M., and Hunter, J. C. (1998). Distribution of the tetrodotoxin-resistant sodium chan nel PN3 in rat sensory neurons in normal and neuropathic conditions. J. Neurosci. 18, 2174-2187.
88. Patapoutian, A., Tate, S., and Woolf, C. J. (2009). Transient receptor potential channels: targeting pain at the source. Nat. Rev. Drug Discov. 8, 55-68.
89. Persson, A. K., Thun, J., Xu, X. J., Wiesenfeld-Hallin, Z., Strom, M., Devor, M., Lidman, O., and Fried, K. (2009). Autotomy behavior correlates with the DRG and spinal expression of sodium channels in inbred mouse strains. Brain Res. 1285, 1-13.
90. Priest, B. T., Murphy, B. A., Lindia, J. A., Diaz, C., Abbadie, C., Ritter, A. M., Liberator, P., Iyer, L. M., Kash, S. F., Kohler, M. G., Kaczorowski, G. J., Macintyre, D. E., and Martin, W. J. (2005). Contribution of the tetrodotoxin-resistant voltage-gated sodium channel NaV1.9 to sensory transmission and nociceptive behavior. Proc. Natl. Acad. Sci. U.S.A. 102, 9382-9387.
91. Rajamani, S., El-Bizri, N., Shryock, J. C., Makielski, J. C., and Belar-dinelli, L. (2009). Use-dependent block of cardiac late Na(+) current by ranolazine. Heart Rhythm 6, 1625-1631.
92. Rajamani, S., Shryock, J. C., and Belardinelli, L. (2008). Block of tetrodotoxin-sensitive, Na(V)1.7 and tetrodotoxin-resistant, Na(V)1.8, Na+ channels by ranolazine. Channels (Austin) 2, 449-460.
93. Raman, I. M., and Bean, B. P. (1997). Resurgent sodium current and action potential formation in dissociated cerebellar Purkinje neurons. J. Neurosci. 17, 4517-4526.
94. Reimann, F., Cox, J. J., Belfer, I., Diatchenko, L., Zaykin, D. V., Mchale, D. P., Drenth, J. P., Dai, F., Wheeler, J., Sanders, F., Wood, L., Wu, T. X., Karppinen, J., Niko-lajsen, L., Mannikko, M., Max, M. B., Kiselycznyk, C., Poddar, M., Te Morsche, R. H., Smith, S., Gibson, D., Kelempisioti, A., Maixner, W., Gribble, F. M., and Woods, C. G. (2010). Pain perception is altered by a nucleotide polymorphism in SCN9A. Proc. Natl. Acad. Sci. U.S.A. 107, 5148-5153.
95. Renganathan, M., Cummins, T. R., and Waxman, S. G. (2001). Contribution of Na(v)1.8 sodium channels to action potential electrogenesis in DRG neurons. J. Neurophysiol. 86, 629-640.
96. Rivera-Acevedo, R. E., Pless, S. A., Ahern, C. A., and Schwarz, S. K. (2011). The quaternary lidocaine derivative, QX-314, exerts bipha-sic effects on transient receptor potential vanilloid subtype 1 channels in vitro. Anesthesiology 114, 1425-1434.
97. Roberson, D., Binshtok, A., Blasl, F., Bean, B., and Woolf, C. (2011). Targeting of sodium channel block-ers into nociceptors to produce long-duration analgesia: a systematic study and review. Br. J. Pharmacol. 164, 48-58.
98. Romettino, S., Lazdunski, M., and Gottesmann, C. (1991). Anticonvul-sant and sleep-waking influences of riluzole in a rat model of absence epilepsy. Eur. J. Pharmacol. 199, 371-373.
99. Rush,A.M.,andCummins,T.R. (2007). Painful research: identification of a small-molecule inhibitor that selectively targets Nav1.8 sodium channels. Mol. Interv. 7, 192-195.
100. Rush,A. M., Cummins, T. R., and Wax-man, S. G. (2007). Multiple sodium channels and their roles in elec-trogenesis within dorsal root ganglion neurons. J. Physiol. (Lond.) 579, 1-14.
101. Rush, A. M., Dib-Hajj, S. D., Liu, S., Cummins, T. R., Black, J. A., and Waxman, S. G. (2006). A single sodium channel mutation produces hyper- or hypoexcitabil-ity in different types of neurons. Proc. Natl. Acad. Sci. U.S.A. 103, 8245-8250.
102. Sangameswaran, L., Delgado, S. G., Fish, L. M., Koch, B. D., Jakeman, L. B., Stewart, G. R., Sze, P., Hunter, J. C., Eglen, R. M., and Herman, R. C. (1996). Structure and function of a novel voltage-gated, tetrodotoxin-resistant sodium channel specific to sensory neurons. J. Biol. Chem. 271, 5953-5956.
103. Sangameswaran, L., Fish, L. M., Koch, B. D., Rabert, D. K., Delgado, S. G., Ilnicka, M., Jakeman, L. B., Novakovic, S., Wong, K., Sze, P., Tzoumaka, E., Stewart, G. R., Herman, R. C., Chan, H., Eglen, R. M., and Hunter, J. C. (1997). A novel tetrodotoxin-sensitive, voltage-gated sodium channel expressed in rat and human dorsal root ganglia. J. Biol. Chem. 272, 14805-14809.
104. Scanio, M. J., Shi, L., Drizin, I., Gregg, R. J., Atkinson, R. N., Thomas, J. B., Johnson, M. S., Chapman, M. L., Liu, D., Krambis, M. J., Liu, Y., Shieh, C. C., Zhang, X., Simler, G. H., Joshi, S., Honore, P., Marsh, K. C., Knox, A., Werness, S., Antonio, B., Krafte, D. S., Jarvis, M. F., Faltynek, C. R., Mar-ron, B. E., and Kort, M. E. (2010). Discovery and biological evaluation of potent, selective, orally bioavail-able, pyrazine-based blockers of the Na(v)1.8 sodium channel with efficacy in a model of neuropathic pain. Bioorg. Med. Chem. 18, 7816-7825.
105. Schmalhofer, W. A., Calhoun, J., Burrows, R., Bailey, T., Kohler, M. G., Weinglass, A. B., Kaczorowski, G. J., Garcia, M. L., Koltzenburg, M., and Priest, B. T. (2008). ProTx-II, a selective inhibitor of NaV1.7 sodium channels, blocks action potential propagation in nociceptors. Mol. Pharmacol. 74, 1476-1484.
106. Schwarz, S. K., Cheung, H. M., Ries, C. R., Lee, S. M., Wang, J. T., and Macleod, B. A. (2010). Lum bar intrathecal administration of the quaternary lidocaine derivative, QX-314, produces irritation and death in mice. Anesthesiology 113, 438-444.
107. Sheets, P. L., Heers, C., Stoehr, T., and Cummins, T. R. (2008). Differential block of sensory neuronal voltage-gated sodium channels by lacosamide [(2R)-2-(acetylamino)-N-benzyl-3-methoxypropanamide], lidocaine, and carbamazepine. J. Pharmacol. Exp. Ther. 326, 89-99.
108. Siqueira, S. R., Alves, B., Malpar-tida, H. M., Teixeira, M. J., and Siqueira, J. T. (2009). Abnormal expression of voltage-gated sodium channels Nav1.7, Nav1.3 and Nav1.8 in trigeminal neuralgia. Neuroscience 164, 573-577.
109. Song, J. H., Huang, C. S., Nagata, K., Yeh, J. Z., and Narahashi, T. (1997). Differential action of rilu-zole on tetrodotoxin-sensitive and tetrodotoxin-resistant sodium channels. J. Pharmacol. Exp. Ther. 282, 707-714.
110. Stohr, T., Krause, E., and Selve, N. (2006). Lacosamide displays potent antinociceptive effects in animal models for inflammatory pain. Eur. J. Pain 10, 241-249.
111. Thakor, D. K., Lin, A., Matsuka, Y., Meyer, E. M., Ruangsri, S., Nishimura, I., and Spigelman, I. (2009). Increased peripheral nerve excitability and local NaV1.8 mRNA up-regulation in painful neuropathy. Mol. Pain 5, 14.
112. Theile, J. W., and Cummins, T. R. (2011). Inhibition of Nav{beta}4 peptide-mediated resurgent sodium currentsinNav1.7channelsbycarba-mazepine, riluzole and anandamide. Mol. Pharmacol. 80,724-734.
113. Theile, J. W., Jarecki, B. W., Piekarz, A. D., and Cummins, T. R. (2011). Nav1.7 mutations associated with paroxysmal extreme pain disorder, but not erythromelalgia, enhance Nav{beta}4 peptide-mediated resurgent sodium currents. J. Physiol. 589, 597-608.
114. Toledo-Aral, J. J., Moss, B. L., He, Z. J., Koszowski, A. G., Whise-nand, T., Levinson, S. R., Wolf, J. J., Silos-Santiago, I., Halegoua, S., and Mandel, G. (1997). Identification of PN1, a predominant voltage-dependent sodium channel expressed principally in peripheral neurons. Proc. Natl. Acad. Sci. U.S.A. 94, 1527-1532.
115. Tominaga, M., Caterina, M. J., Malm-berg, A. B., Rosen, T. A., Gilbert, H., Skinner, K., Raumann, B. E., Basbaum,A. I., and Julius, D. (1998). The cloned capsaicin receptor integrates multiple pain-producing stimuli. Neuron 21, 531-543.
116. Tyagarajan, S., Chakravarty, P. K., Zhou, B., Fisher, M. H., Wyvratt, M. J., Lyons, K., Klatt, T., Li, X., Kumar, S., Williams, B., Felix, J., Priest, B. T., Brochu, R. M., Warren, V., Smith, M., Garcia, M., Kaczorowski, G. J., Martin,W. J., Abbadie, C., Mcgowan, E., Jochnowitz, N., and Parsons, W. H. (2010a). Substituted biaryl oxa-zoles, imidazoles, and thiazoles as sodium channel blockers. Bioorg. Med. Chem. Lett. 20, 5536-5540.
117. Tyagarajan, S., Chakravarty, P. K., Zhou, B., Taylor, B., Eid, R., Fisher, M. H., Parsons, W. H., Wyvratt, M. J., Lyons, K. A., Klatt, T., Li, X., Kumar, S., Williams, B., Felix, J., Priest, B. T., Brochu, R. M., Warren, V., Smith, M., Garcia, M., Kaczorowski, G. J., Martin, W. J., Abbadie, C., Mcgowan, E., Jochnowitz, N., Weber, A., and Duffy, J. L. (2010b). Discovery of a novel class of biphenyl pyrazole sodium channel block-ers for treatment of neuropathic pain. Bioorg. Med. Chem. Lett. 20, 7479-7482.
118. Tyagarajan, S., Chakravarty, P. K., Zhou, B., Taylor, B., Fisher, M. H., Wyvratt, M. J., Lyons, K., Klatt, T., Li, X., Kumar, S., Williams, B., Felix, J., Priest, B. T., Brochu, R. M., Warren, V., Smith, M., Garcia, M., Kaczorowski, G. J., Martin, W. J., Abbadie, C., Mcgowan, E., Jochnowitz, N., and Parsons, W. H. (2010c). Substituted biaryl pyrazoles as sodium channel blockers. Bioorg. Med. Chem. Lett. 20, 5480-5483.
119. Urbani,A.,and Belluzzi,O. (2000). Rilu-zole inhibits the persistent sodium current in mammalian CNS neurons. Eur. J. Neurosci. 12, 3567-3574.
120. Vassilev, P. M., Scheuer, T., and Cat-terall, W. A. (1988). Identification of an intracellular peptide segment involved in sodium channel inacti-vation. Science 241, 1658-1661.
121. Walia, K. S., Khan, E. A., Ko, D. H., Raza, S. S., and Khan, Y. N. (2004). Side effects of antiepileptics - a review. Pain Pract. 4, 194-203.
122. Wang, G. K., Calderon, J., and Wang, S. Y. (2008). State- and use-dependent block of muscle Nav1.4 and neu-ronal Nav1.7 voltage-gated Na+ channel isoforms by ranolazine. Mol. Pharmacol. 73, 940-948.
123. Wang,Y., Park,K. D.,Salome,C.,Wilson, S. M., Stables, J. P., Liu, R., Khanna, R., and Kohn, H. (2011). Development and characterization of novel derivatives of the antiepileptic drug lacosamide that exhibit far greater enhancement in slow inactivation of voltage-gated sodium channels. ACS Chem. Neurosci. 2, 90-106.
124. Waxman, S. G., and Dib-Hajj, S. (2005). Erythermalgia: molecular basis for an inherited pain syndrome. Trends Mol. Med. 11, 555-562.
125. Waxman, S. G., Kocsis, J. D., and Black, J. A. (1994). Type III sodium channel mRNA is expressed in embryonic but not adult spinal sensory neurons, and is reexpressed following axotomy. J. Neurophysiol. 72, 466-470.
126. Weiser, T., and Wilson, N. (2002). Inhibition of tetrodotoxin (TTX)-resistant and TTX-sensitive neu-ronal Na(+) channels by the secre-tolytic ambroxol. Mol. Pharmacol. 62, 433-438.
127. Weiss, S., Benoist, D., White, E., Teng, W., and Saint, D. A. (2010). Riluzole protects against cardiac ischaemia and reperfusion damage via block of the persistent sodium current. Br. J. Pharmacol. 160, 1072-1082.
128. West, J. W., Patton, D. E., Scheuer, T., Wang, Y., Goldin,A. L., and Catterall, W. A. (1992). A cluster of hydropho-bic amino acid residues required for fast Na(+)-channel inactivation. Proc. Natl. Acad. Sci. U.S.A. 89, 10910-10914.
129. Wymer, J. P., Simpson, J., Sen, D., and Bongardt, S. (2009). Efficacy and safety of lacosamide in diabetic neuropathic pain: an 18-week double-blind placebo-controlled trial of fixed-dose regimens. Clin. J. Pain 25, 376-385.
130. Xiao, Y., Blumenthal, K., Jackson, J. O. II, Liang, S., and Cummins, T. R. (2010). The tarantula toxins ProTx-II and huwentoxin-IV differentially interact with human Nav1.7 voltage sensors to inhibit channel activation and inactivation. Mol. Pharmacol. 78, 1124-1134.
131. Xie, R. G., Zheng, D. W., Xing, J. L., Zhang, X. J., Song, Y., Xie, Y. B., Kuang, F., Dong, H., You, S. W., Xu, H., and Hu, S. J. (2011). Blockade of persistent sodium currents contributes to the riluzole-induced inhibition of spontaneous activity and oscillations in injured DRG neurons. PLoS ONE 6, e18681. doi:10.1371/journal.pone.0018681
132. Yang, B. H., Piao, Z. G., Kim, Y. B., Lee, C. H., Lee, J. K., Park, K., Kim, J. S., and Oh, S. B. (2003). Activation of vanilloid receptor 1 (VR1) by eugenol. J. Dent. Res. 82, 781-785.
133. Yu, Y. Q., Zhao, F., Guan, S. M., and Chen, J. (2011). Antisense-mediated knockdown of Na(V)1.8, but not Na(V)1.9, generates inhibitory effects on complete Freund's adjuvant-induced inflammatory pain in rat. PLoS One 6, e19865. doi:10.1371/journal.pone.0019865
134. Zgrajka, W., Nieoczym, D., Czuczwar, M., Kis, J., Brzana, W., Wlaz, P., and Turski, W. A. (2010). Evidences for pharmacokinetic interaction of riluzole and topiramate with pilocarpine in pilocarpine-induced seizures in rats. Epilepsy Res. 88, 269-274.
135. Zhang, X. F., Shieh, C. C., Chapman, M. L., Matulenko, M. A., Hakeem, A. H., Atkinson, R. N., Kort, M. E., Marron, B. E., Joshi, S., Hon-ore, P., Faltynek, C. R., Krafte, D. S., and Jarvis, M. F. (2010). A-887826 is a structurally novel, potent and voltage-dependent Na(v)1.8 sodium channel blocker that attenuates neuropathic tactile allody-nia in rats. Neuropharmacology 59, 201-207.
136. Ziegler, D., Hidvegi, T., Gurieva, I., Bon-gardt, S., Freynhagen, R., Sen, D., and Sommerville, K. (2010). Efficacy and safety of lacosamide in painful diabetic neuropathy. Diabetes Care 33, 839-841.
137. Zorn, S., Leipold, E., Hansel, A., Bulaj, G., Olivera, B. M., Terlau, H., and Heinemann,S.H. (2006). ThemuO-conotoxin MrVIA inhibits voltage-gated sodium channels by associating with domain-3. FEBS Lett. 580, 1360-1364.